Zentalis Pharmaceuticals

ZNTL

Market cap $118M

Overview Fund Trends Analyst Outlook Journalist POV

1.64 USD

+0.01

0.61%

At close Updated Oct 23, 4:00 PM EDT

Pre-market

After hours

1.67

+0.03

1.83%

1 day

0.61%

5 days

6.49%

1 month

9.33%

3 months

8.61%

6 months

9.33%

Year to date

-45.33%

1 year

-50.6%

5 years

-96.07%

10 years

-92.93%

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166

Healthcare Biotechnology